---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-065386"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2025-07-02T23:59:59+00:00"
generated_at: "2026-05-18T09:41:55.298948+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ArriVent BioPharma prices $75M public offering of common stock and pre-funded warrants

## Summary
- Raised ~$75M gross; priced 2,482,692 shares at $19.50 and 1,363,469 pre-funded warrants at $19.4999.
- Underwriters have 30-day option to purchase up to 576,923 additional shares on same terms.
- Proceeds to fund firmonertinib and other pipeline programs, plus working capital.
- Expected close July 3, 2025; joint bookrunners: Goldman Sachs, Citigroup, Guggenheim Securities.

## SEC filing metadata
- accession: 0001104659-25-065386
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2025-07-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000110465925065386/0001104659-25-065386-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000110465925065386/tm2519401d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-065386
- JSON: https://secwatch.observer/filing/0001104659-25-065386.json
- Plain text: https://secwatch.observer/filing/0001104659-25-065386.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.